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Summary Lonidamine [1-(2,4-dichlorobenzyl)-1-H-indazol-3-carboxylic acid] is shown to inhibit recovery
from potentially lethal damage after exposure of cells to X-rays, methyl methane sulfonate, or bleomycin and
heat (43°C, 1 h). Inhibition is most effective when the drug is present before and after exposure of 10 to
25mgl-1, a concentration readily achieveable in vivo.
Survival of cells exposed to cytotoxic agents can be
modified by their post-exposure environment.
Phillips & Tolmach (1966) suggested that
irradiation (or exposure to other agents) produces
two classes of cells: those that have irreversibly lost
their ability for unlimited proliferation; and an
intermediate, unstable class whose ultimate fate is
determined by the post exposure conditions. In
particular, a favorable milieu (for survival) leads to
higher rate of reconversion ofintermediate to viable
cells ("recovery"), while an unfavorable environ-
ment favours conversion to dead cells ("fixation of
damage"). These authors coined the term
potentially lethal damage (PLD) to describe that
component of damage that was found to be
recoverable under the conditions of the experiment
performed. One of the methods frequently
employed to test for the ability of cells to recover
from PLD is to leave them, after the treatment, in a
density-inhibited state for various lengths of time,
and then to test for their colony forming ability
(Hahn & Little, 1972). Any increase in survival
over that seen in cells subcultured to low density
immediately after exposure is interpreted as
evidence for recovery. Using this technique,
recovery has been shown to occur after X and UV
irradiation, as well as after treatment of cells with
alkylating agents and with the glycopeptide
bleomycin (Hahn, 1976). This procedure is quite
analogous to testing for liquid-holding recovery in
bacteria.
Surprisingly few compounds have been shown to
inhibit recovery after X-irradiation or after drug
treatments (Evans et al., 1974). Illiakis (1980) has
demonstrated that some nucleoside analogues such
as f,-arabinofuranosyladenine have this capability,
and Guichard et al. (1979) have presented evidence
that the radiosensitizer misonidazole also has this
property. For both these compounds, however, the
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doses required are so high that their use in the
clinic is probably associated with excessive toxicity.
Therefore the finding of any new agent able to
inhibit PLD recovery is of considerable interest. We
show here that lonidamine is such a compound and
that inhibition of PLD recovery occurs at drug
concentrations that are readily and safely
achievable in humans.
Materials and methods
Chinese hamster cells (HA-1) were maintained in
Eagle's minimal essential medium (MEM)
supplemented with 15% foetal calf serum and
antibiotics. The cultures were kept in a humidified
incubator at 37°C, and pH was maintained with a
mixture of 95% air and 5% CO2. We obtained
plateau phase cells by seeding 1-2 x I05 cells into
60mm plastic petri dishes. Medium was changed
daily beginning with the third day. Experiments
were always performed on the eighth day at a cell
density of 106cellscm-2. At least 80% of the
cells were in a non-cycling G1 like phase of the cell
cycle. The assay to test for recovery from
potentially lethal damage (PLD) involved varying
the time between the end of a particular treatment
and trypsinization and replating at low cell density
for colony formation. Experiments were performed
at least twice, sometimes 3 times. While there were
experiment-to-experiment variations, these did not
affect any of the conclusions drawn. Data presented
are from a representative experiment.
X-irradiation
Cells were irradiated at room temperature with a
Phillips commercial X-ray unit operating at 85 kVp,
9.6 mA, dose rate - 0.95Gymin -1.
Drug exposure
Lonidamine was made up in a stock solution with
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dimethyl sulfoxide (DMSO) as the solvent. At the
highest lonidamine concentration used, 50mgl-1,
the medium contained 1% DMSO. For this reason,
1% DMSO controls, without lonidamine, were
always included. Lonidamine so dissolved was non-
toxic to cells for exposures of 50mgl-1 and for up
to 24h. Methyl methane sulfonate (MMS), at a
concentration of 600mgl-1 was dissolved in MEM
not containing serum. Bleomycin was used at a
concentration of 50mgl-1 and it was also dissolved
in MEM without serum. In experiments requiring
drug removals or exchanges, cells were washed
twice in MEM without serum before new medium
containing different drugs, or no drugs, was added
to the dishes.
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Results
X-irradiation
Several types of experiments were performed to
examine the ability of the drug to interfere with the
recovery from PLD. We tested the need for the
agent to be present during, before or after X-ray.
Drug present only before X-ray had no effect on
survival. Results of the other experiments are
shown in Figures 1-3. The first of these shows that
doses up to 25mg 1-l are unable to abolish
recovery if the drug is present only before and
during X-irradiation. The second figure, however,
shows that if lonidamine is present after irradiation,
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Figure 1 Survival of plateau phase HA-1 cells after
X-irradiation: lonidamine before and during X-ray.
Cells were incubated in Hank's Balanced Salt Solution
(HBSS) with lonidamine (concentration as indicated)
for 16h before being given 12-Gy of 80kVp X-rays.
Immediately after irradiation, one group of cells was
trypsinized and plated for colony formation. The other
2 groups were rinsed and incubated in HBSS without
lonidamine for either 3 or 6h and then trypsinized.
(0) no lonidamine; (L) 10mgl1- lonidamine; (A)
25 mg 1- 1 lonidamine.
Figure 2 Survival of plateau phase HA-I cells after
X-irradiation: lonidamine after X-rays. Cells were
given 12-Gy and then either trypsinized and plated for
colony formation or reincubated in lonidamine in
HBSS at the indicated concentrations. (0) no
lonidamine; (A) 0mgl- I lonidamine; ([l) 50mg 1-
lonidamine.
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Figure 3 Survival of plateau phase HA-l cells after
X-irradiation: lonidamine before, during and after X-
ray. Protocol as in Figure 1, except that cells were
maintained in HBSS with lonidamine until
trypsinization at the indicated times. (0) no
lonidamine; (A) 10mgP1 lonidamine.
it inhibits recovery. At a dose of 50mg1 1,
recovery is completely inhibited. Finally, in Figure
3 we show results of an experiment in which the
drug was present before, during and after
irradiation. Under such conditions the presence in
the medium of 10mgl-l is sufficient to completely
inhibit any increase in survival. Higher doses,
although by themselves completely non-toxic,
increase the radiation-induced cell lethality below
control values, thus favoring "fixation" of X-ray
damage.
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Methyl methane sulfonate
Figure 4 shows results of a very similar experiment
to the one just described, but using MMS as the
cytotoxic agent. Again the ability of lonidamine to
interfere with recovery is clearly seen. Where
lonidamine was present both before and after MMS
exposure, additional inhibition of recovery was
seen.
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Figure 4 Survival of plateau phase HA-1 cells after
MMS exposure: lonidamine after drug exposure. Cells
were exposed to MMS (20min, 600mg1-1) and then
either plated for colony formation or incubated in
HBSS with lonidamine until trypsinization at the
indicated times. One group of cells also had
lonidamine (25mgl-1) present for 16h before as well
as after drug exposure. (0) no lonidamine; (A)
10mgl-l lonidamine; (E1) 25mgl-1 lonidamine. (K)
50mg 1- lonidamine. (V) 25mgl1- lonidamine before
and after MMS exposure.
Bleomycin
HA-1 cells are relatively resistant to this drug. Its
cytotoxicity is, however, greatly enhanced at
elevated temperatures (Braun & Hahn, 1975). We
therefore exposed cells for 40min at 43°C followed
by 1 h bleomycin treatment and then tested their
ability to recover from PLD at 37°C. Results are
shown in Figure 5. Again lonidamine's ability to
interfere with recovery is apparent, although the
magnitude of the effect is smaller than after either
X-irradiation or MMS. When lonidamine was
present before and after bleomycin and heat, a
small additional amount of inhibition was seen
(data not shown).
Twentyman & Bleehen (1975) have suggested that
there is no recovery from PLD after bleomycin
treatment, but only a time-dependent disappearance
of a trypsin-bleomycin interaction. Specifically, they
suggest that trypsin permits membrane-bound drug
to enter the cell. If this were the case, our data on
bleomycin might have no clinical relevance. While
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Figure 5 Survival of plateau phase HA-1 cells after
bleomycin and heat: lonidamine after treatment. Cells
were first heated at 430C for 40min; this was followed
by bleomycin (50mg -1, 1 h). They were then either
plated for colony formation or incubated at 37°C in
HBSS with or without lonidamine until trypsinization
at the indicated times. (0) no lonidamine; (A)
25mgP1 lonidamine.
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Figure 6 Repair of potentially lethal damage after
heat and bleomycin exposures. Cells were trypsinized,
diluted, plated at appropriate concentrations and
allowed to attach for 6h. They were then rinsed twice
with medium and then returned to the 37°C incubator
for an additional 12h. Then they were heated (43°C,
40min) and exposed to bleomycin (50mg - 1; 1 h). At
the indicated times, the medium was replaced with
hypotonic phosphate-buffered saline (0.63M PBS).
Twenty minutes later, the buffer was removed,
medium added and the cells placed in the incubator
for colony formation. An additional heat only control
showed no effects of the hypotonic buffer treatment.
In another experiment, hypertonic phosphate-buffered
saline (1.83 M PBS) was used; results were
indistinguishable from those shown.
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the results presented in Figure 5 are difficult to
rationalize on that basis, nevertheless we performed
experiments to test for PLD recovery in a system
that does not involve trypsinization. We utilized the
technique of interrupting recovery by exposing cells
to a non-isotonic environment (Utsumi & Elkind,
1979). Results for hypotonic exposures are shown
in Figure 6. Clearly, recovery did occur, even
though in these experiments no trypsinisation was
involved. In another experiment we used hypertonic
medium; results were similar to those presented.
Discussion
The data presented here show lonidamine can
inhibit recovery from PLD caused by X-rays,
MMS, or by bleomycin and heat. These agents
were chosen because earlier studies had shown that
PLD recovery from exposures could be
demonstrated in the plateau phase system. We have
no data that can be used to determine how
lonidamine accomplishes this. Some clue may be
obtained, however, by considering the drug's mode
of action as a cytotoxic agent. Lonidamine is said
to act against cells by interfering with the integrity
of condensed mitochondria, and thereby
presumably disrupting energy metabolism. It is a
reasonable hypothesis to suggest that this is also an
explanation for its anti-recovery action because Jain
et al. (1982) have recently demonstrated that, at
least in X-irradiated yeast, recovery from PLD is an
energy-requiring process. This hypothesis is
certainly consistent with our finding that
lonidamine is most effective when it is present in
the cultures both before and after irradiation.
Weichselbaum et al. (1977) have presented data
which argue that the radiation resistance of some
tumours, particularly melanomas, may be related to
an unusual capacity of cells from such tumours to
deal with PLD. If this is correct, then the chronic
administration of lonidamine during a fractionated
course of radiotherapy might well make such
lesions much more responsive to X-rays. Any
possible therapeutic effect would also have to take
into account PLD recovery in normal tissues. Our
results also suggest that the drug may be of use
during poly-drug chemotherapy.
An advantageous aspect of our finding is that the
toxicity and pharmaco-kinetics of this drug are
already being studied extensively. Lonidamine is
currently undergoing phase I and II studies at
several institutions, both in the U.S. and in
Canada, as well as in Italy, for possible anti-
tumour activity. Plasma levels of 10mgl-1 and
even higher have been found to be readily
achievable and are apparently not accompanied by
undue toxicities. Therefore this drug may be
suitable for clinical testing in the near future.
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